Research Article
Construction and Validation of a Novel Immune Checkpoint-Related Model in Clear Cell Renal Cell Carcinoma
Figure 8
The impact of the KIRC-ICG model on immune therapy response. (a) Difference in TIDE score between the two KIRC-ICG subgroups. (b) Correlation between TIDE score and KIRC-ICGsore. (c) Difference in KIRC-ICGscore between CR/PR and SD/PD group in the IMvigor210 cohort. (d) The Kaplan-Meier curve between the two KIRC-ICG subgroups after atezolizumab therapy. .
(a) |
(b) |
(c) |
(d) |